Acharya Ganesh, Singh Kulbir, Hansen John Bjarne, Kumar Satish, Maltau Jan Martin
Department of Obstetrics and Gynecology, University Hospital of Northern Norway, Postbox 24, N-9038 Tromsø, Norway.
Acta Obstet Gynecol Scand. 2005 Feb;84(2):155-8. doi: 10.1111/j.0001-6349.2005.00565.x.
Catheter-directed thrombolysis that removes the thrombus and restores patency of the veins appears to be a safe and effective management of acute deep venous thrombosis (DVT). It has been shown to reduce long-term postthrombotic morbidity and improve the quality of life. Pregnancy and the postpartum period are generally considered as contraindications for thrombolysis. However, catheter-directed thrombolytic therapy of DVT may reduce long-term sequelae in these young patients by restoring the patency of veins. The purpose of this pilot study was to evaluate the efficacy of catheter-directed thrombolysis in treating acute symptomatic postpartum DVT.
Patients enrolled had symptomatic acute DVT (<3 weeks duration) within 42 days of childbirth. Thrombolysis was performed using a recombinant human tissue plasminogen activator, alteplase 5 mg i.v. bolus, followed by an infusion at 0.01 mg/kg/h for the next 20-24 hr. Unfractionated heparin 5000 IU bolus followed by 300 IU/kg/24 hr was infused concomitantly into an arm vein. Fibrinogen and cephotest were obtained every 6 hr and maintained at >1 g/l and between 50 and 70 s, respectively, by adjusting heparin and alteplase infusion. Venography was repeated after 20-24 hr and angioplasty (+/- stenting) was performed if stenosis was present. In case of partial thrombolysis infusion was continued for a maximum of 96 hr. Lysis was considered complete if there was less than 5% residual luminal area narrowing. The treatment was considered successful if there was complete or partial resolution of lower extremity pain and edema, and recanalization of vein with less than 30% residual luminal area narrowing. Following thrombolytic therapy, patients were fitted with graduated compression stockings, and anticoagulated with oral warfarin for 1 year (or lifelong in case of stent implantation).
Five women with postpartum DVT (four iliofemoral DVTs, and one renal and ovarian vein thrombosis on the left side) had catheter-directed thrombolysis. The treatment was successful in all four cases of iliofemoral DVT and symptom relief was achieved in all five cases. However, despite partial thrombolysis and restoration of some flow in the patient with renal and ovarian vein thrombosis, the renography performed 1 month later showed absent left kidney function.
Where expertise exists, endovascular therapy consisting of catheter-directed thrombolysis with angioplasty and stenting in selected cases could be considered as a primary therapeutic procedure in patients with acute postpartum DVT.
导管定向溶栓术可清除血栓并恢复静脉通畅,似乎是急性深静脉血栓形成(DVT)的一种安全有效的治疗方法。已证明其可降低血栓形成后的长期发病率并改善生活质量。妊娠和产后时期通常被视为溶栓的禁忌证。然而,导管定向溶栓治疗DVT可能通过恢复静脉通畅来减少这些年轻患者的长期后遗症。这项前瞻性研究的目的是评估导管定向溶栓治疗急性症状性产后DVT的疗效。
纳入的患者在分娩后42天内出现症状性急性DVT(病程<3周)。使用重组人组织型纤溶酶原激活剂阿替普酶进行溶栓,静脉推注5 mg,随后在接下来的20 - 24小时内以0.01 mg/kg/h的速度输注。同时将5000 IU的普通肝素静脉推注,然后以300 IU/kg/24小时的速度输注到手臂静脉中。每6小时检测一次纤维蛋白原和凝血酶原时间,并通过调整肝素和阿替普酶的输注使其分别维持在>1 g/l和50至70秒之间。20 - 24小时后重复静脉造影,如果存在狭窄则进行血管成形术(±支架置入)。如果是部分溶栓,则输注最多持续96小时。如果残留管腔面积狭窄小于5%,则认为溶栓完全。如果下肢疼痛和水肿完全或部分消退,且静脉再通且残留管腔面积狭窄小于30%,则认为治疗成功。溶栓治疗后,患者穿着分级压力弹力袜,并口服华法林抗凝1年(如果植入支架则终身抗凝)。
5例产后DVT女性患者(4例髂股DVT,1例左侧肾静脉和卵巢静脉血栓形成)接受了导管定向溶栓治疗。4例髂股DVT患者的治疗均成功,所有5例患者的症状均得到缓解。然而,尽管左侧肾静脉和卵巢静脉血栓形成的患者进行了部分溶栓并恢复了一些血流,但1个月后进行的肾造影显示左肾功能丧失。
在具备专业技术的情况下,对于急性产后DVT患者,由导管定向溶栓联合血管成形术及在特定病例中进行支架置入组成的血管内治疗可被视为主要治疗方法。